Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07295717 | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers | PHASE1 | RECRUITING | 76 | — | — | Dec 12, 2025 | Mar 23, 2027 | May 14, 2026 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| ALN-4285 | EXPERIMENTAL | Participants will be administered ALN-4285 subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered placebo SC |
| Name | Type | Description |
|---|---|---|
| ALN-4285 | DRUG | ALN-4285 will be administered SC |
| Placebo | DRUG | Placebo will be administered SC |
Inclusion Criteria: * Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2 * Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator Exclusion Criteria: * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST)...